Zhejiang Laifual Drive leads the group, targeting $146.7 million to scale its production of robotic components. As China's second-largest supplier of harmonic reducers, the firm intends to move into broader precision transmission solutions while expanding its overseas sales reach. Its IPO prices range from HK$77.00 to HK$85.50 per share.

The biotechnology sector is also well-represented in this wave of listings. Guangdong True Health Medical Technology seeks up to HK$482.7 million to advance its surgical robotics, specifically tools used for ablation and puncture procedures. Simultaneously, Jiangxi Institute of Biological Products plans to raise HK$473.2 million. While Jiangxi maintains its position as the world's largest provider of human tetanus antitoxins, the firm’s latest filings project a substantial decline in net profit for the current year.

These listings arrive amid a resurgence in Hong Kong’s financial activity, with the exchange reporting HK$166.8 billion raised in the first five months of 2026—more than double the volume from the same period last year. Provided the current timelines hold, shares for all three companies are scheduled to begin trading on June 30.